Diplomat launches online specialty pharmacy resource targeting both patients and clinicians
FLINT, Mich. — A new web platform has gone live from Diplomat, the nation’s largest independent specialty pharmacy reported Thursday. On Jan. 29 the company revealed a completely redesigned site that is "mobile-friendly, easy to use and primed for upcoming changes."
The venture, titled ‘Diplomat.is,’ is the latest tech project to emerge from Diplomat, a firm that posted more than $1.5 billion in revenue for 2013. According to Jennifer Cretu, VP information technology and marketing, the unveiling is part of a new move.
“We deployed this site to become a better resource for people with questions about specialty pharmacy care,” Cretu said. “More and more people are bringing those questions to the web, and this new site is an answer for them — a simpler way for patients and providers to find the tools and insights they’re looking for.”
Meanwhile, the site’s URL lends itself to memorable connections, ranging from diplomat.is/oncology to diplomat.is/copayhelp. The site’s content will be updated frequently and offer resources for anyone interested in the field, including patients, families, physicians and professionals across health care, Diplomat stated.
“At Diplomat, we’ve always positioned our expertise so we can use it to help others,” Cretu said. “With this new project, we can meet those people no matter where they are. And this launch is just the beginning.”
For regular visitors to Diplomat’s previous site, diplomatpharmacy.com will automatically redirect to the new site at diplomat.is.
Ateb adds two heavy hitters to its roster
RALEIGH, N.C. — Ateb recently named Rebecca Chater as its executive healthcare strategist and added Bjorn Thommesen to the team.
Chater will provide clinical leadership of Ateb’s patient care support solutions and thought leadership to influence broad integration of pharmacy and pharmacist services among healthcare stakeholders to improve patient care coordination and health outcomes.
Chater brings to Ateb more than twenty years of professional leadership and innovation and was a pioneer in the historical Asheville Project, which continues to serve as a model for delivering health solutions and patient-centric care through community pharmacy to improve health outcomes and lower overall costs.
Chater is a past president and 10-year elected-member of the North Carolina Board of Pharmacy, and has served as Visiting Clinical Assistant Professor in the department of pharmacotherapy at the University of North Carolina Eshelman School of Pharmacy. She is a recipient of the North Carolina Association of Pharmacists Innovative Practice Award and the UNC Eshelman School of Pharmacy Distinguished Service Award. She earned both her master’s degree in public health and her bachelor of science in pharmacy at the University of North Carolina at Chapel Hill.
Thommesen will focus on providing solutions for pharmacy to better patient health and increase adherence. He comes to Ateb from RxAlly to provide his expertise in consultative selling, business development and health plan and payer solutions.
Thommesen has more than a decade of experience in consultative selling to Medicare, Medicaid and commercial health plans and employers. His emphasis has been on solutions that improve healthcare delivery and patient health outcomes, while reducing costs for payers and increasing quality and member satisfaction scores, including HEDIS, STAR and CAHPS.
Before joining Ateb, Thommesen worked for such industry leaders as HealthPartners, UnitedHealthCare, Amerigroup Corporation and Express Scripts. Thommesen has a proven track record of helping lower healthcare costs by facilitating relationships between advanced clinical programs and community pharmacists and patients. In support of the same goals, both Ateb and Thommesen are determined to continue to assist pharmacies to be recognized and remunerated for providing patient-centric care and clinical solutions to improve patient health outcomes.
Teva approved for new dose of Copaxone
JERUSALEM — Teva Pharmaceutical Industries on Tuesday announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL. Daily Copaxone in 20mg/mL dosage will continue to be available.
Copaxone is administered to patients with relapsing forms of multiple sclerosis. The new formulation will allow for a less frequent dosing regimen.
“The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for patients, as they now have the option of effective and safe treatment with Copaxone, while reducing the number of injections by 60%,” Omar Khan, M.D., professor of neurology and chair of the department of neurology at Wayne State University School of Medicine, said. “Patients in the United States can now benefit from an improved dosing regimen without compromising the known benefits of Copaxone.”
Three-times-a-week Copaxone 40mg/mL is available for shipping immediately.